Findings of Scientific Misconduct, 32619-32620 [05-11017]
Download as PDF
<![CDATA[
FOR FURTHER INFORMATION CONTACT:
Sandra M. Peay, Contract Representative
Or
Renee Hallman, Case Management
Assistant, Federal Trade Commission,
Premerger Notification Office, Bureau of
Competition, Room H–303, Washington,
DC 20580, (202) 326–3100.
By Direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 05–11027 Filed 6–2–05; 8:45 am]
BILLING CODE 6750–01–C
Alternative Fuel Vehicle Acquisition
and Compliance Report is available online at https://www.knownet.hhs.gov/log/
AgencyPolicy/HHSLogPolicy/
afvcompliance.htm
Jim
Kerr at (202) 720–1904, or via e-mail at
jim.kerr@hhs.gov.
FOR FURTHER INFORMATION CONTACT:
Dated: May 24, 2005.
Evelyn M. White,
Acting Assistant Secretary for Administration
and Management.
[FR Doc. 05–11075 Filed 6–2–05; 8:45 am]
BILLING CODE 4161–17–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Fleet Alternative Fuel Vehicle
Acquisition and Compliance Report
Department of Health and
Human Services (HHS).
ACTION: Notice of availability.
AGENCY:
18:03 Jun 02, 2005
Jkt 205001
Findings of Scientific Misconduct
AGENCY:
ACTION:
SUMMARY: Pursuant to 42 United States
Code 13218(b), the Department of
Health and Human Services gives notice
that the Department’s FY 2004 Fleet
VerDate jul<14>2003
Office of the Secretary
Office of the Secretary, HHS.
Notice.
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI),
the Acting Assistant Secretary for
Health, and another Federal agency
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
32619
have taken final action in the following
case:
Jason W. Lilly, Ph.D., Boyce
Thompson Institute: Based on the report
of an investigation conducted by the
Boyce Thompson Institute (BTI Report),
the investigation report of another
Federal agency, and additional analysis
conducted by ORI in its oversight
review, the U.S. Public Health Service
(PHS) found that Jason W. Lilly, Ph.D.,
former postdoctoral fellow at BTI,
engaged in scientific misconduct in
research supported by the National
Research Service Award, National
Institutes of Health (NIH) postdoctoral
fellowship, F32 GM64276. This case has
been jointly handled by ORI and
another Federal agency under the
government-wide debarment
regulations.
Specifically, PHS found that:
A. Dr. Lilly falsified Figure 4,
presenting a hierarchical cluster
analysis of differential mRNA
accumulation in cells grown in medium
deficient in sulfate or phosphate in
‘‘The Chlamydonomas reinhardtii
organellar genomes respond
transcriptionally and posttranscriptionally to abiotic stimuli,’’ The
E:\FR\FM\03JNN1.SGM
03JNN1
EN03JN05.008</GPH>
Federal Register / Vol. 70, No. 106 / Friday, June 3, 2005 / Notices
32620
Federal Register / Vol. 70, No. 106 / Friday, June 3, 2005 / Notices
Plant Cell 14:2681:2706, 2002 (hereafter
referred to as the Plant Cell paper) by
claiming it was an average of three
experiments when only one had been
conducted;
B. Dr. Lilly further falsified Figure 4
of the Plant Cell paper by falsely
coloring two cells in the blown-up
portion of the figure that illustrated the
induction of high levels of mRNA from
the Sac1 gene;
C. Dr. Lilly falsified the supplemental
gene array experiments published
online claimed to be replicate assays by
manipulation of both spreadsheet and
image data from a single assay to make
the altered data sufficiently different to
appear to be separate assays;
D. Dr. Lilly falsified the text
describing Figure 5 of the Plant Cell
paper by claiming that the run-on assays
had been replicated when they had not
been;
E. Dr. Lilly falsified the purported
replicates of run-on transcription
experiments provided in the on-line
supplemental material by manipulation
of a single assay to make the variant
versions appear different; and
F. Dr. Lilly falsified Figure 1 of the
Plant Cell paper by using the same 16S
control bands for RNA blots of two
different genes (psbF and PsaG).
Dr. Lilly has been debarred by the
lead agency for a period of two (2) years,
beginning on March 4, 2005, and ending
on March 4, 2007, and has entered into
a Voluntary Exclusion Agreement
(Agreement ) with PHS in which he has
voluntarily agreed:
(1) To exclude himself from serving in
any advisory capacity to PHS including
but not limited to service on any PHS
advisory committee, board, and/or peer
review committee, or as consultant, for
a period of four (4) years, beginning on
April 18, 2005; and
(2) That he will ensure that any
institution employing him submits, in
conjunction with each application for
PHS funds or report, manuscript, or
abstract of PHS funded research in
which Dr. Lilly is involved, a
certification that the data provided by
Dr. Lilly are based on actual
experiments or are otherwise
legitimately derived, and that the data,
procedures, and methodology are
accurately reported in the application or
report for a period of two (2) years,
beginning on April 18, 2007,
approximately corresponding to the
termination date of the debarment
period initiated by the lead agency. Dr.
Lilly must ensure that the institution
also sends a copy of the certification to
ORI.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
VerDate jul<14>2003
18:03 Jun 02, 2005
Jkt 205001
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (301) 443–5330.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. 05–11017 Filed 6–2–05; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Sentinel Network for Detecting
Emerging Infections Among Allograft
Donors and Recipients
Announcement Type: New.
Funding Opportunity Number:
AA081.
Catalog of Federal Domestic
Assistance Number: 93.283.
Key Dates:
Letter of Intent Deadline: July 5, 2005.
Application Deadline: August 2, 2005.
Executive Summary: Over the last
decade, there has been a large increase
in the number of allografts (e.g., solid
organs and other tissues) recovered from
donors for use in transplants. Each year
in the United States, over 25,000 solid
organs are recovered, and over a million
tissue allografts are distributed for lifesaving transplantations, including bone,
musculoskeletal, vascular, and corneal
tissues. Organs and tissues are
distributed to different settings: Organs
are distributed to transplant services in
hospitals, and tissues are distributed to
tissue banks, biotechnology companies,
and healthcare consignees, including
hospitals, outpatient centers, and
individual surgeons. A single donor
with undetected infection potentially
can infect over a hundred organ and
tissue recipients located around the
world. In addition, tissues may be
stored for up to ten years; thus,
infections may be transmitted to
recipients many years after the death of
the donor. Recent investigations have
demonstrated severe infections and
death from transmission of various
agents from donors to recipients,
including: Clostridia spp. (e.g., C.
sordellii, C. perfringens, C. septicum),
West Nile virus, Group A Streptococcus,
Trypanosoma cruzi, Lymphocytic
choriomeningitis virus, rabies virus, and
others. A recent Institute of Medicine
report highlighted the urgent need to
detect infectious diseases among organ
and tissue donor and transplant
recipients. Recently, additional
regulatory mechanisms have been put in
place. For solid organs, through the
Organ Procurement and Transplantation
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
Network (OPTN), new standards have
been put in place to detect and report
adverse events among organ transplant
recipients; for other tissues, there will
be new FDA rules for organ and tissue
procurement organizations (OPOs) and
tissue banks, implemented May 1, 2005.
Despite these new regulatory standards,
challenges remain. A surveillance
network for surveillance of allograftassociated infections that would
enhance communication between public
health officials and organizations
responsible for recovering and
processing tissues would have high
potential as a tool for risk assessment
and response, in collaboration with
regulatory efforts.
I. Funding Opportunity Description
Authority: 42 U.S.C. 247b(k)(2)
Purpose: The purpose of the program
is to develop a national sentinel
network of organizations that recover,
process, and distribute tissues from
organ/tissue donors. The participants in
this activity can include OPOs, tissue
processors, tissue distributors, and
others. This collection of participants
has been termed the tissue community.
At present, many procurement
organizations provide regional tissue
recovery services. This program
addresses the ‘‘Healthy People 2010’’
focus area(s) of Immunization and
Infectious Diseases.
Measurable outcomes of the program
will be in alignment with the following
performance goal for the National
Center for Infectious Diseases (NCID):
Protect Americans from death and
serious harm caused by medical errors
and preventable complications of
healthcare.
This announcement is only for nonresearch activities supported by CDC/
ATSDR. If research is proposed, that
portion of any application will not be
reviewed or considered for funding. For
the definition of research, please see the
CDC Web site at the following Internet
address: https://www.cdc.gov/od/ads/
opspoll1.htm.
Objectives
The objective of the network will be
to detect and prevent emerging
infectious diseases through:
• Improved communication among
those in the tissue community (e.g.,
tissue recovery organizations, OPOs that
recover tissues, tissue processors, tissue
distributors), healthcare facilities, and
public health officials, concerning
potential risks for transmission of
infection.
• Improved identification and
tracking of tissues to facilitate
E:\FR\FM\03JNN1.SGM
03JNN1
]]>Agencies
[Federal Register Volume 70, Number 106 (Friday, June 3, 2005)]
[Notices]
[Pages 32619-32620]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-11017]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI), the Acting Assistant Secretary for Health, and another Federal
agency have taken final action in the following case:
Jason W. Lilly, Ph.D., Boyce Thompson Institute: Based on the
report of an investigation conducted by the Boyce Thompson Institute
(BTI Report), the investigation report of another Federal agency, and
additional analysis conducted by ORI in its oversight review, the U.S.
Public Health Service (PHS) found that Jason W. Lilly, Ph.D., former
postdoctoral fellow at BTI, engaged in scientific misconduct in
research supported by the National Research Service Award, National
Institutes of Health (NIH) postdoctoral fellowship, F32 GM64276. This
case has been jointly handled by ORI and another Federal agency under
the government-wide debarment regulations.
Specifically, PHS found that:
A. Dr. Lilly falsified Figure 4, presenting a hierarchical cluster
analysis of differential mRNA accumulation in cells grown in medium
deficient in sulfate or phosphate in ``The Chlamydonomas reinhardtii
organellar genomes respond transcriptionally and post-transcriptionally
to abiotic stimuli,'' The
[[Page 32620]]
Plant Cell 14:2681:2706, 2002 (hereafter referred to as the Plant Cell
paper) by claiming it was an average of three experiments when only one
had been conducted;
B. Dr. Lilly further falsified Figure 4 of the Plant Cell paper by
falsely coloring two cells in the blown-up portion of the figure that
illustrated the induction of high levels of mRNA from the Sac1 gene;
C. Dr. Lilly falsified the supplemental gene array experiments
published online claimed to be replicate assays by manipulation of both
spreadsheet and image data from a single assay to make the altered data
sufficiently different to appear to be separate assays;
D. Dr. Lilly falsified the text describing Figure 5 of the Plant
Cell paper by claiming that the run-on assays had been replicated when
they had not been;
E. Dr. Lilly falsified the purported replicates of run-on
transcription experiments provided in the on-line supplemental material
by manipulation of a single assay to make the variant versions appear
different; and
F. Dr. Lilly falsified Figure 1 of the Plant Cell paper by using
the same 16S control bands for RNA blots of two different genes (psbF
and PsaG).
Dr. Lilly has been debarred by the lead agency for a period of two
(2) years, beginning on March 4, 2005, and ending on March 4, 2007, and
has entered into a Voluntary Exclusion Agreement (Agreement ) with PHS
in which he has voluntarily agreed:
(1) To exclude himself from serving in any advisory capacity to PHS
including but not limited to service on any PHS advisory committee,
board, and/or peer review committee, or as consultant, for a period of
four (4) years, beginning on April 18, 2005; and
(2) That he will ensure that any institution employing him submits,
in conjunction with each application for PHS funds or report,
manuscript, or abstract of PHS funded research in which Dr. Lilly is
involved, a certification that the data provided by Dr. Lilly are based
on actual experiments or are otherwise legitimately derived, and that
the data, procedures, and methodology are accurately reported in the
application or report for a period of two (2) years, beginning on April
18, 2007, approximately corresponding to the termination date of the
debarment period initiated by the lead agency. Dr. Lilly must ensure
that the institution also sends a copy of the certification to ORI.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (301) 443-5330.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. 05-11017 Filed 6-2-05; 8:45 am]
BILLING CODE 4150-31-P
